Description

CLOFERT 100 MG (1X5)

Indications

CLOFERT 100 MG is primarily indicated for the treatment of female infertility due to ovulatory dysfunction. It is often prescribed for women who have irregular menstrual cycles or conditions such as polycystic ovary syndrome (PCOS) that impede ovulation. CLOFERT is also utilized in assisted reproductive technologies, including in vitro fertilization (IVF), to enhance the chances of conception by stimulating ovarian follicular development.

Mechanism of Action

The active ingredient in CLOFERT is clomiphene citrate, a selective estrogen receptor modulator (SERM). Clomiphene works by binding to estrogen receptors in the hypothalamus, which leads to a decrease in the negative feedback of estrogen on the hypothalamus and pituitary gland. This action stimulates the release of gonadotropin-releasing hormone (GnRH), which subsequently increases the secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the pituitary. The rise in FSH levels promotes ovarian follicular development, while increased LH levels trigger ovulation.

Pharmacological Properties

CLOFERT is absorbed rapidly from the gastrointestinal tract, with peak plasma concentrations occurring approximately 6 to 12 hours after oral administration. The drug has a half-life of about 5 to 7 days, allowing for sustained effects on the hypothalamic-pituitary-ovarian axis. Clomiphene citrate is metabolized in the liver and excreted primarily via the feces, with a smaller proportion eliminated through urine. Its pharmacokinetic profile supports its use in cycles of ovulation induction, typically administered for five consecutive days during the early follicular phase of the menstrual cycle.

Contraindications

CLOFERT should not be used in women who are hypersensitive to clomiphene citrate or any of the excipients in the formulation. It is contraindicated in cases of liver disease, uncontrolled thyroid disorders, adrenal dysfunction, and ovarian cysts not related to polycystic ovary syndrome. Additionally, it should not be administered during pregnancy or lactation, as the safety of clomiphene in these conditions has not been established.

Side Effects

Common side effects associated with CLOFERT include hot flashes, abdominal discomfort, and nausea. Some women may experience mood swings, headaches, or visual disturbances such as blurred vision. In rare instances, more serious side effects may occur, including ovarian hyperstimulation syndrome (OHSS), which can lead to abdominal pain, swelling, and even severe complications if left untreated. It is essential for patients to report any unusual symptoms to their healthcare provider promptly.

Dosage and Administration

The typical starting dose of CLOFERT is 50 mg taken orally once daily for five days, beginning on the fifth day of the menstrual cycle. Depending on the patient’s response, the dose may be increased to 100 mg in subsequent cycles. Monitoring of ovarian response through ultrasound and serum hormone levels is recommended to avoid complications such as OHSS. It is crucial to follow the prescribing physician’s recommendations regarding dosage adjustments and treatment duration.

Interactions

CLOFERT may interact with other medications, potentially affecting its efficacy or increasing the risk of side effects. Co-administration with other fertility medications, such as gonadotropins, should be approached with caution and under close medical supervision. Additionally, certain medications that influence liver enzymes may alter the metabolism of clomiphene citrate, necessitating careful monitoring and potential dose adjustments.

Precautions

Before starting treatment with CLOFERT, a thorough medical history and physical examination are essential to rule out contraindications. Patients should be monitored for signs of ovarian hyperstimulation syndrome and other adverse effects throughout the treatment cycle. Women with a history of thromboembolic disorders should use CLOFERT with caution, as there may be an increased risk of thrombosis. Regular follow-up appointments are necessary to assess the patient’s response to therapy and adjust the treatment plan as needed.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of CLOFERT in inducing ovulation in women with anovulatory infertility. For instance, a study published in the Journal of Clinical Endocrinology & Metabolism reported that clomiphene citrate was successful in inducing ovulation in approximately 80% of women with PCOS. Furthermore, research has indicated that the combination of CLOFERT with other fertility treatments can enhance pregnancy rates, particularly in women undergoing assisted reproductive technologies. However, the potential risks associated with its use, including multiple pregnancies and OHSS, underscore the importance of careful patient selection and monitoring.

Conclusion

CLOFERT 100 MG is a well-established medication for the treatment of ovulatory dysfunction in women seeking to conceive. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable option in infertility management. However, it is essential for healthcare providers to consider contraindications, potential side effects, and the importance of monitoring during treatment. With appropriate use and guidance, CLOFERT can significantly improve the chances of successful ovulation and conception in eligible patients.